Featured Research

from universities, journals, and other organizations

Synthetic Protein Eases Arthritis Symptoms In Mice

Date:
October 4, 2005
Source:
NIH/National Institute of Allergy and Infectious Diseases
Summary:
A lab-made version of a human protein alleviates symptoms of both acute and chronic arthritis in mice and could be the basis for a new arthritis drug for people, report scientists from the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH). The protein prevents the assembly of a cell surface receptor, thus blocking transmission of chemical signals that lead to arthritis symptoms.

A lab-made version of a human protein alleviates symptoms of both acuteand chronic arthritis in mice and could be the basis for a newarthritis drug for people, report scientists from the NationalInstitute of Allergy and Infectious Disease (NIAID), part of theNational Institutes of Health (NIH). The protein prevents the assemblyof a cell surface receptor, thus blocking transmission of chemicalsignals that lead to arthritis symptoms.

"This study opens a new research avenue to better understand and,perhaps, to treat rheumatoid arthritis, a condition that causessuffering in more than two million Americans," says NIAID DirectorAnthony S. Fauci, M.D.

Investigators from NIAID's Laboratory of Immunology, led by MichaelLenardo, M.D., published their findings in the October issue of NatureMedicine, now available online. The idea that the protein, calledpre-ligand assembly domain protein or PLAD, might play a role inthwarting the joint inflammation characteristic of rheumatoidarthritis--one of the most common autoimmune diseases--grew out oftheir research on a very rare autoimmune disease called autoimmunelymphoproliferative syndrome (ALPS).

Previously, Dr. Lenardo and his colleagues showed that in ALPS a formof PLAD blocks a cell surface receptor and prevents a needed chemicalsignaling pathway from functioning correctly. In ALPS, the signalpathway interrupted by PLAD leads to disease symptoms. But, thescientists reasoned, PLAD might also be able to block a related cellsurface receptor--one involved in passing signals that lead toinflammation. In theory, inhibiting this pathway might benefit peoplewith rheumatoid arthritis, who suffer from excessive inflammation.

A key promoter of inflammation is a chemical called tumornecrosis factor alpha (TNF-alpha). TNF-alpha starts a chemical chainreaction leading to inflammation by binding to two cell surfacereceptors, TNFR-1 and TNFR-2. Naturally occurring PLAD helps both formsof TNFR assemble and prepare to receive TNF-alpha. Synthetic PLAD, thescientists hypothesized, would bind to its natural counterpart andprevent it from performing its usual task.

The scientists used a variety of techniques (including injection ofTNF-alpha) to induce arthritis symptoms in mice. Researchers alsoinjected some of the animals with lab-made PLAD (P60 PLAD). "We foundthat P60 PLAD protein powerfully inhibited the symptoms ofTNF-alpha-induced arthritis," says Dr. Lenardo. P60 PLAD also lessenedthe effects of arthritis induced by other means. Moreover, he adds, P60PLAD appeared to inhibit disease symptoms in mice with established aswell as acute arthritis. The scientists did not detect any obvioustoxicity in the PLAD-treated mice.

"We're very hopeful that this could be good news for arthritissufferers," says Dr. Lenardo. In particular, the researchers areintrigued by P60 PLAD's apparent specificity: it seems to block thebinding of TNF-alpha to TNFR-1, while allowing TNFR-2 to continue tofunction. This is important, notes Dr. Lenardo, because it mayrepresent an advantage over some currently used arthritis drugs, whichdirectly block TNF-alpha by binding to both TNFRs and thereby inhibitbeneficial actions mediated by TNFR-2.

The scientists next aim to develop a more stable form of P60 PLAD. Ultimately, they hope to test the protein in clinical trials.

###

The research was also supported by the National Institute of General Medical Sciences, part of the NIH.

NIAID is a component of the National Institutes of Health, an agency ofthe U.S. Department of Health and Human Services. NIAID supports basicand applied research to prevent, diagnose and treat infectious diseasessuch as HIV/AIDS and other sexually transmitted infections, influenza,tuberculosis, malaria and illness from potential agents ofbioterrorism. NIAID also supports research on transplantation andimmune-related illnesses, including autoimmune disorders, asthma andallergies.

Reference: G-M Deng et al. Amelioration of inflammatoryarthritis by targeting the pre-ligand assembly domain (PLAD) of tumornecrosis factor receptors. Nature Medicine. Published online September18, 2005. DOI: 10.1038/nm1304.



Story Source:

The above story is based on materials provided by NIH/National Institute of Allergy and Infectious Diseases. Note: Materials may be edited for content and length.


Cite This Page:

NIH/National Institute of Allergy and Infectious Diseases. "Synthetic Protein Eases Arthritis Symptoms In Mice." ScienceDaily. ScienceDaily, 4 October 2005. <www.sciencedaily.com/releases/2005/10/051004083602.htm>.
NIH/National Institute of Allergy and Infectious Diseases. (2005, October 4). Synthetic Protein Eases Arthritis Symptoms In Mice. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2005/10/051004083602.htm
NIH/National Institute of Allergy and Infectious Diseases. "Synthetic Protein Eases Arthritis Symptoms In Mice." ScienceDaily. www.sciencedaily.com/releases/2005/10/051004083602.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins